News
The 6th IDIBELL sLHam of women scientists will claim the role of women and girls in science
The event will be in the Barradas Auditorium in L’Hospitalet de Llobregat on Friday, February 10, at 7 p.m. The 6th sLHam incorporates a novelty: Together with six woman scientists from IDIBELL, two junior sLHamers from the Bellvitge Institute will participate.
New treatment options are opening up in the field of cutaneous lymphomas thanks to an immunotherapy-based drug
According to the results, brentuximab vedotin is effective and safe for some rare types of cutaneous T-cell lymphomas (LCCT)
A group of excellence composed of IDIBELL researchers and Cardiology professionals from the HUB joins the CIBER of Cardiovascular Diseases
The group linked to IDIBELL investigates personalized precision strategies for the interdisciplinary approach to heart failure in its evolutionary phases. Their research will contribute to the objective of the CIBERCV: reduce the impact of cardiovascular diseases and develop actions of excellence in translational cardiovascular research and training.
Dr. Josep Comín, co-author of two publications in Nature Medicine and JACC on a new drug against heart failure
The international group of scientists who have discovered the benefits of dapagliflozin in the treatment of heart failure, including Dr. Josep Comín, head of the IDIBELL BIO-Heart Research Group on Cardiovascular Diseases and the Cardiology Service of the Hospital de Bellvitge, has published new disaggregated results of this research in the leading scientific journals Nature Medicine and the Journal of the American College of Cardiology (JACC).
Two brain regions size could predict the psychological behavioral therapy effectiveness in children with OCD
A study by the Bellvitge Biomedical Research Institute (IDIBELL), the Bellvitge University Hospital, the University of Barcelona, and CIBERSAM observes that children with increased volume of two prefrontal cortex structures respond better to cognitive behavioral therapy.
Presentation of the new confocal microscope of the Bioimaging platform
The Bioimaging Platform of the IDIBELL Scientific-technical Services has incorporated a new high-performance equipment, which is the Carl Zeiss LSM980 confocal microscope equipped with the Airyscan2 detector
Allogeneic transplantation from a matched registry donor may have better results than that from a less well-matched relative
A study led by the Catalan Institute of Oncology and IDIBELL, published in the scientific journal ‘Transplantation and Cellular Therapy’, concludes that, whenever possible, it is better for the patient to receive a transplant from a highly compatible registry donor than from a haploidentical donor with a family relationship, but less compatible.
Viladecans Against Cancer donates €25,000 to IDIBELL for research into personalized medicine for this disease
The donation, the result of the solidarity campaigns organized by the Association throughout 2022, will be used to finance the generation of a new experimental model for the study of predisposition to cancer, a project based on personalized medicine, and the use of stem cells to modeling diseases.
A drug that boosts the regeneration of stem cells extends life expectancy in mice
The work focuses on endogenous blood stem cell rejuvenation as a possible strategy to regenerate tissues and improve the health and life expectancy of the elderly.